About the Authors
- Wen Li
-
Contributed equally to this work with: Wen Li, Akico Okuda
Affiliation Laboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Hyogo, Japan
- Akico Okuda
-
Contributed equally to this work with: Wen Li, Akico Okuda
Affiliations Laboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Hyogo, Japan, Department of Pathology, Hyogo College of Medicine, Hyogo, Japan
- Hideyuki Yamamoto
-
Affiliation Laboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Hyogo, Japan
- Kyosuke Yamanishi
-
Affiliations Laboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Hyogo, Japan, Department of Neuropsychiatry, Hyogo College of Medicine, Hyogo, Japan
- Nobuyuki Terada
-
Affiliation Department of Pathology, Hyogo College of Medicine, Hyogo, Japan
- Hiromichi Yamanishi
-
Affiliation Hirakata General Hospital for Developmental Disorders, Hirakata, Osaka, Japan
- Yoshimasa Tanaka
-
Affiliation Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Haruki Okamura
-
* E-mail: haruoka@hyo-med.ac.jp
Affiliation Laboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Hyogo, Japan
Competing Interests
The authors have read the journal's policy and have the following conflicts: The study was funded in part by Astellas Pharma Inc. Recombinant human IL-18 and ZOL were kindly provided by GlaxoSmithKline plc (Research Triangle Park, NC) and Novartis AG (Basel, Switzerland), respectively. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and material.
Author Contributions
Conceived and designed the experiments: HO WL. Performed the experiments: WL AO KY NT H. Yamanishi YT. Analyzed the data: WL H. Yamamoto. Contributed reagents/materials/analysis tools: YT. Wrote the paper: HO WL. Revised the manuscript: NT YT. Discussions: HO WL AO H. Yamamoto KY NT H. Yamanishi YT.